Genome-wide association studies of antidepressant outcome: A brief review

Gonzalo Laje, Francis J. McMahon

Research output: Contribution to journalArticle

Abstract

Genome-wide association studies (GWAS) of antidepressant treatment outcome have been at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match medications with patients, maximizing efficacy while minimizing adverse effects. The hypothesis-free approach of the GWAS has the advantage of interrogating genes that otherwise would have not been considered as candidates due to our limited understanding of their function, and may also uncover important regulatory variation within the large regions of the genome that do not contain protein-coding genes. Three independent samples have so far been studied using a genome-wide approach: The Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) (n = 1953), the Munich Antidepressant Response Signature (MARS) sample (n = 339) and the Genome-based Therapeutic Drugs for Depression (GENDEP) sample (n = 706). None of the studies reported results that achieved genome-wide significance, suggesting that larger samples and better outcome measures will be needed. This review discusses the published GWAS studies, their strengths, limitations, and possible future directions.

Original languageEnglish (US)
Pages (from-to)1553-1557
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume35
Issue number7
DOIs
StatePublished - Aug 15 2011
Externally publishedYes

Fingerprint

Genome-Wide Association Study
Antidepressive Agents
Genome
Pharmacogenetics
Psychiatry
Outcome Assessment (Health Care)
Therapeutics
Pharmaceutical Preparations
Genes
Proteins

Keywords

  • Antidepressant treatment outcome
  • Genome-wide association
  • GWAS
  • Pharmacogenetics
  • Pharmacogenomics

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Genome-wide association studies of antidepressant outcome : A brief review. / Laje, Gonzalo; McMahon, Francis J.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 7, 15.08.2011, p. 1553-1557.

Research output: Contribution to journalArticle

@article{528570d48a2d42359b5f9e2eca0cdb23,
title = "Genome-wide association studies of antidepressant outcome: A brief review",
abstract = "Genome-wide association studies (GWAS) of antidepressant treatment outcome have been at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match medications with patients, maximizing efficacy while minimizing adverse effects. The hypothesis-free approach of the GWAS has the advantage of interrogating genes that otherwise would have not been considered as candidates due to our limited understanding of their function, and may also uncover important regulatory variation within the large regions of the genome that do not contain protein-coding genes. Three independent samples have so far been studied using a genome-wide approach: The Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) (n = 1953), the Munich Antidepressant Response Signature (MARS) sample (n = 339) and the Genome-based Therapeutic Drugs for Depression (GENDEP) sample (n = 706). None of the studies reported results that achieved genome-wide significance, suggesting that larger samples and better outcome measures will be needed. This review discusses the published GWAS studies, their strengths, limitations, and possible future directions.",
keywords = "Antidepressant treatment outcome, Genome-wide association, GWAS, Pharmacogenetics, Pharmacogenomics",
author = "Gonzalo Laje and McMahon, {Francis J.}",
year = "2011",
month = "8",
day = "15",
doi = "10.1016/j.pnpbp.2010.11.031",
language = "English (US)",
volume = "35",
pages = "1553--1557",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Genome-wide association studies of antidepressant outcome

T2 - A brief review

AU - Laje, Gonzalo

AU - McMahon, Francis J.

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Genome-wide association studies (GWAS) of antidepressant treatment outcome have been at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match medications with patients, maximizing efficacy while minimizing adverse effects. The hypothesis-free approach of the GWAS has the advantage of interrogating genes that otherwise would have not been considered as candidates due to our limited understanding of their function, and may also uncover important regulatory variation within the large regions of the genome that do not contain protein-coding genes. Three independent samples have so far been studied using a genome-wide approach: The Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) (n = 1953), the Munich Antidepressant Response Signature (MARS) sample (n = 339) and the Genome-based Therapeutic Drugs for Depression (GENDEP) sample (n = 706). None of the studies reported results that achieved genome-wide significance, suggesting that larger samples and better outcome measures will be needed. This review discusses the published GWAS studies, their strengths, limitations, and possible future directions.

AB - Genome-wide association studies (GWAS) of antidepressant treatment outcome have been at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match medications with patients, maximizing efficacy while minimizing adverse effects. The hypothesis-free approach of the GWAS has the advantage of interrogating genes that otherwise would have not been considered as candidates due to our limited understanding of their function, and may also uncover important regulatory variation within the large regions of the genome that do not contain protein-coding genes. Three independent samples have so far been studied using a genome-wide approach: The Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) (n = 1953), the Munich Antidepressant Response Signature (MARS) sample (n = 339) and the Genome-based Therapeutic Drugs for Depression (GENDEP) sample (n = 706). None of the studies reported results that achieved genome-wide significance, suggesting that larger samples and better outcome measures will be needed. This review discusses the published GWAS studies, their strengths, limitations, and possible future directions.

KW - Antidepressant treatment outcome

KW - Genome-wide association

KW - GWAS

KW - Pharmacogenetics

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=79961126893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961126893&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2010.11.031

DO - 10.1016/j.pnpbp.2010.11.031

M3 - Article

C2 - 21115088

AN - SCOPUS:79961126893

VL - 35

SP - 1553

EP - 1557

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 7

ER -